As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/21/20  Aerie Pharmaceuticals Inc         8-K:7,9     1/21/20   11:161K                                   Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K 
11: R1          Document and Entity Information                     HTML     49K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
10: XML         XBRL Instance -- d870371d8k_htm                      XML     13K 
 6: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- aeri-20200121_lab                     XML     55K 
 5: EX-101.PRE  XBRL Presentations -- aeri-20200121_pre              XML     35K 
 3: EX-101.SCH  XBRL Schema -- aeri-20200121                         XSD     12K 
 7: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
 9: ZIP         XBRL Zipped Folder -- 0001193125-20-010537-xbrl      Zip     12K 

 i AERIE PHARMACEUTICALS INC  i false  i 0001337553 0001337553 2020-01-21 2020-01-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM  i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i January 21, 2020

Aerie Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

i Delaware		i 001-36152		i 20-3109565
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

 i 4301 Emperor Boulevard,  i Suite 400

 i Durham,  i North Carolina  i 27703

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code:  i (919)  i 237-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Shares of common stock, par value $0.001 per share		i AERI		i Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company   i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 7.01.

Regulation FD Disclosure.

On January 21, 2020, Aerie Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that its sterile fill production facility in Athlone, Ireland has received approval from U.S. Food and Drug Administration (FDA) to produce Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful preapproval inspection of the facility and FDA review of the New Drug Application Prior Approval Supplement (PAS), which added the Athlone production facility as a drug product manufacturer for Rocklatan^®. A copy of this press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a determination or admission by the Company that this information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:

	99.1			Press Release dated January 21, 2020.
	104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				AERIE PHARMACEUTICALS, INC.
Date: January 21, 2020				By:		/s/ Richard J. Rubino
						Richard J. Rubino
						Chief Financial Officer